Aprameya EngineeringNSE:APRAMEYA -0.54%42 9-Day RSI is 34.52 as of Jul. 11, 2026. GuruFocus rates NSE:APRAMEYA with a GF Score™ of 42/100. The stock has 6 warning signs investors should review. Among 869 Medical Devices & Instruments companies, Aprameya Engineering ranks better than 80.21% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for Aprameya Engineering's 9-Day RSI or its related term are showing as below:
NSE:APRAMEYA's 9-Day RSI is ranked better than 80.21% of 869
companies
in the Medical Devices & Instruments industry
Industry Median: 46.94
vs NSE:APRAMEYA: 34.52
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Aprameya Engineering 9-Day RSI Related Terms
NSE:APRAMEYA vs ISRG, BDX, MDLN: 9-Day RSI Comparison
For the Medical Instruments & Supplies subindustry, Aprameya Engineering's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aprameya Engineering 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aprameya Engineering's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Aprameya Engineering's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aprameya Engineering (NSE:APRAMEYA) has a 9-Day RSI of 34.52 as of Jul. 11, 2026. According to the industry distribution chart, Aprameya Engineering ranks #172 out of 869 companies in the Medical Devices & Instruments industry, placing it in the top 19.8%.
Is Aprameya Engineering's 9-Day RSI too high?
Aprameya Engineering's current 9-Day RSI is 34.52. The Medical Devices & Instruments industry median 9-Day RSI is 46.94. Aprameya Engineering's value of 34.52 is 26.5% below this industry median. Based on the distribution chart, Aprameya Engineering ranks #172 out of 869 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Aprameya Engineering has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Aprameya Engineering's 9-Day RSI compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Aprameya Engineering ranks #172 out of 869 companies for 9-Day RSI. This places Aprameya Engineering in the top 20% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 46.94. Aprameya Engineering's value of 34.52 is 26.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 46.94, based on 869 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aprameya Engineering's current 9-Day RSI of 34.52 is 26.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 46.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aprameya Engineering's current 9-Day RSI is 34.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprameya Engineering stock overvalued right now?
Aprameya Engineering (NSE:APRAMEYA) has a current 9-Day RSI of 34.52. The current 9-Day RSI is 34.52 and 26.5% below the Medical Devices & Instruments industry median of 46.94. Aprameya Engineering's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Aprameya Engineering (NSE:APRAMEYA), the current 9-Day RSI is 34.52 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aprameya Engineering Ltd is engaged in the business of installation, set up & maintenance of Intensive Care Units (ICU), Neonatal Intensive Care Units (NICU), Pediatric Intensive Care Units (PICU), Operation Theatre, dialysis centres and prefabricated structure ward (hereinafter referred to as Healthcare Infrastructure projects) in the hospitals and medical care centers on turnkey basis with the supply of high-value healthcare equipment and diagnostic equipment to private hospitals, Government hospitals, and medical practitioners. The company has two Business segments: Trading of Medical support Equipment (Trading Sales) and Supplies for Infra Projects for health care sectors (Turnkey project supplies). Key revenue is generated from Trunkey Project Supply.
42GF Score
Get the complete analysis for NSE:APRAMEYA
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:APRAMEYA has been successfully added to your 